ELADUR is a proprietary, long-acting transdermal patch to treat pain associated with post-herpetic neuralgia (PHN). It is intended to deliver the local anesthetic bupivacaine to the affected area for a period of up to 3 days after a single application.
- Longer duration (3 days versus 12 hours) and fewer incidents of breakthrough pain than existing lidocaine patches for PHN
- Thinner and lighter, with less skin irritation for improved wearability
- Next generation adhesive for sweat and water resistance
Post-herpetic neuralgia (PHN) is a term that describes persistent neuropathic pain following an outbreak of shingles, a later-in-life complication of childhood chicken pox. Shingles typically occurs as a localized painful rash years after an initial infection with the varicella zoster (chicken pox) virus. In about 5%-30% of cases, depending on age and immune status, the pain fails to subside with resolution of the rash, and may become long-lasting, severe, and debilitating.
The prevalence of PHN (clinically significant pain lasting more than 3 months) has been estimated at approximately 144,000 people in the U.S. The pain associated with PHN can be difficult to treat with systemic drugs, but because it affects sensory nerves projecting to discrete areas of skin, it can be addressed with topically-applied anesthetic agents such as lidocaine and bupivacaine. Worldwide sales of branded and generic lidocaine patches totaled $1.5 billion in 2014.
ELADUR is currently in Phase 2 development, with Impax directing the clinical program.
There are risks and uncertainties associated with our business. Please see our most recent SEC filings (10-K or 10-Q) for a complete description of these risks and uncertainties, which are incorporated herein by reference.